All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
Remitogen
National Institutes of Health
Topic mentions per year
Topic mentions per year
2001-2001
0
1
2001
2001
Related topics
Related topics
1 relation
Broader (1)
apolizumab
Related mentions per year
Related mentions per year
2001-2009
2000
2002
2004
2006
2008
2010
Remitogen
apolizumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells.
Jia Dong Shi
,
Chuck Bullock
,
+4 authors
Corine K. Klingbeil
Leukemia & lymphoma
2002
The humanized monoclonal antibody Hu1D10 (Remitogen, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of…
(More)
Is this relevant?
2002
2002
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.
Bernhard Stockmeyer
,
Martin R. Schiller
,
+4 authors
Thomas Valerius
British journal of haematology
2002
Antibody-based approaches have become a novel treatment modality for lymphoma patients. Humanized 1D10 (Hu1D10; Remitogen) is…
(More)
Is this relevant?
2002
2002
Host genetics and HIV—removing the mask
Nelson L Michael
Nature Medicine
2002
Is this relevant?
2002
2002
Protein design labs begins Phase I trial of Remitogen in cancer patients with solid tumors.
Expert review of anticancer therapy
2002
Is this relevant?
2001
2001
Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.
K Stephen Brown
,
David Levitt
,
M. P. Shannon
,
Bianca Link
Clinical lymphoma
2001
Is this relevant?